Cargando…

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01)

Detalles Bibliográficos
Autores principales:	Clark, Joseph, Flaherty, Lawrence, Ernstoff, Marc, Koon, Henry, Milhem, Mohammed, Militello, Gerald, Agarwala, Sanjiv, Curti, Brendan, Cranmer, Lee, Lao, Christopher D, Logan, Theodore F, Lutzky, Jose, Rudrapatna, Venkatesh, Daniels, Gregory, Taback, Bret, Aung, Sandra, Lowder, James, Lawson, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288741/ http://dx.doi.org/10.1186/2051-1426-2-S3-P77

Ejemplares similares

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
por: Patel, Sapna, et al.
Publicado: (2014)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
por: Clark, Joseph I., et al.
Publicado: (2018)

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
por: Dutcher, Janice P, et al.
Publicado: (2014)

An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma
por: Hasanov, Merve, et al.
Publicado: (2021)

The genesis of Zelboraf: Targeting mutant B-Raf in melanoma
por: Davis, Matthew J., et al.
Publicado: (2012)

The Proclivities
Publicado: (1856)

Racial Proclivities to Disease
Publicado: (1909)

Update on use of aldesleukin for treatment of high-risk metastatic melanoma
por: Amaria, Rodabe N, et al.
Publicado: (2015)

Physical Characters and Morbid Proclivities
Publicado: (1904)

The Proclivity of Women to Cancerous Disease
Publicado: (1891)

Membrane Stress Proclivities in the Mammalian Labyrinth
por: Pender, Daniel J.
Publicado: (2014)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Scurvy in a patient on vemurafenib
por: Gerstenblith, Meg R., et al.
Publicado: (2014)

Immuno-inflammatory in vitro hepatotoxicity models to assess side effects of biologicals exemplified by aldesleukin
por: Roser, Luise A., et al.
Publicado: (2023)

Prakruti genomics and prameha-proclivity: relevance to metabolic syndrome
por: Vaidya, Ashok DB
Publicado: (2014)

Cultural background shapes spatial reference frame proclivity
por: Goeke, Caspar, et al.
Publicado: (2015)

The Proclivity of Women to Cancerous Diseases, and to Certain Benign Tumours
Publicado: (1892)

On the Proclivity to Phthisis Commonly Ascribed to Persons of Xanthous Complexion
por: Beddoe, John
Publicado: (1858)

Personality correlates of COVID-19 infection proclivity: Extraversion kills()
por: Rolón, Vania, et al.
Publicado: (2021)

Structural and Individual Ageism Predicts Elder Abuse Proclivity and Perpetration
por: Chang, E-Shien, et al.
Publicado: (2021)

Proclivity of nervous system preservation in Cambrian Burgess Shale-type deposits
por: Ortega-Hernández, Javier, et al.
Publicado: (2019)

Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity
por: Houlahan, Kathleen E., et al.
Publicado: (2023)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Inherited proclivity: When should neurogenetics mitigate moral culpability for purposes of sentencing?
por: Segal, J Bradley
Publicado: (2016)

Dehumanization of Older Family Members: Novel Determinants of Elder Abuse Proclivity by Caregivers
por: Chang, E-Shien, et al.
Publicado: (2021)

Osteoid osteomas of the hip: a well-recognized entity with a proclivity for misdiagnosis
por: Wenger, Doris E., et al.
Publicado: (2023)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
por: del Bufalo, Francesca, et al.
Publicado: (2014)

Preclinical Evaluation of Vemurafenib as Therapy for BRAF(V600E) Mutated Sarcomas
por: Gouravan, Sarina, et al.
Publicado: (2018)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
por: Sapkota, Bishu, et al.
Publicado: (2013)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib
por: Car, Iris, et al.
Publicado: (2023)

Insecure Attachment Style and Dysfunctional Sexual Beliefs Predict Sexual Coercion Proclivity in University Men
por: Dang, Silvain S, et al.
Publicado: (2015)

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
por: Chapman, P B, et al.
Publicado: (2017)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
por: Nowara, Elzbieta, et al.
Publicado: (2016)

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation
por: Oneal, Patricia A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2pnuaha2u3spvkp37brb4r7cn6